Blue Lake Biotechnology Secures $5 Million Grant to Support Ongoing Pediatric Phase 1/2a Clinical Trial of Intranasal RSV Vaccine Candidate - The Manila Times
1fuente
1país
1idioma
06:14detectada el 28/10 (12:14 UTC)
06:14última novedad, 28/10
1noticia
Cadena de publicación
La publicó primero The Manila Times (Filipinas) el 28/10 a las 06:14 (12:14 UTC).
-
06:1428/10, 12:14 UTC
MTThe Manila Times news.google.comBlue Lake Biotechnology Secures $5 Million Grant to Support Ongoing Pediatric Phase 1/2a Clinical Trial of Intranasal RSV Vaccine Candidate - The Manila Times
PH EN Primera
Datos de esta historia: JSON





